Chugai Seiyaku Kabushiki Kaisha

Other

Hoffmann-La Roche Inc.

The University of Tokyo

Sakai Toshiyuki

Fumio Watanabe

Sawako Ozawa

Toshihiro Aoki

Naoki Harada

Masahiro Sakaitani

Hitoshi Iikura

Masayuki Matsushita

Noriyuki Furuichi

Pil-Su Ho

Kenichi Kawasaki

Susumu Komiyama

Nobuo Shimma

Takeshi Murata

Hiroshi Fukuda

Hidenori Takahashi

Yasushi Tomii

Kenji Takanashi

Ikumi Hyoudoh

Takuo Tsukuda

Toshihiko Fujii

Nobuhiro Oikawa

Toshiyuki Sakai

Kazuo Hattori

Eisaku Mizuguchi

Tadakatsu Hayase

Yoshiaki Isshiki

Yasunori Kohchi

Toshiyuki Tsukaguchi

Kihito Hada

Nobuya Ishii

Kenji Morikami

Hirosato Ebiike

Miyako Masubuchi

Ikumi Hyodo

Takehiro Okada

Masayuki Sudoh

Kimitaka Nakama

Mikio Taniguchi

Masaki Tomizawa

The present disclosure provides, for example, a compound represented by the general formula below or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt: wherein X, X, Xand Xare each independently —CR═ or N═, Ris, for example, a halogen atom, Ris, for example, —S(═O)—NH—R, Ris, for example, a Calkyl group, Ris, for example, a hydrogen atom, Ris, for example, a halogen atom, Ris, for example, a hydrogen atom, and Ris, for example, a cyclopropyl group. The compounds, salts or solvates provided by the present disclosure exhibit high RAF/MEK complex-stabilizing activity and can be used for the treatment or prevention of cell proliferative disorders, particularly cancers.

Arylamide derivative having antitumor activity

An object of the present invention is to provide a compound that is useful as an orally available anti-HCV agent. The present invention relates to a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. This compound has an anti-HCV activity and is useful as a medicine.

Orally available viridiofungin derivative possessing anti-HCV activity

The present invention provides a p27 protein inducing agent comprising a compound represented by general formula (11) below or pharmaceutically acceptable salt thereof as an active ingredient: wherein G, G, Gand Gare each independently selected from &#x2014;N&#x2550; etc., Ring Gis selected from divalent aryl etc., A is selected from amino etc., Gis selected from oxygen etc., Gis selected from oxygen etc., Gis selected from &#x2014;CH&#x2014; etc., and Ris selected from Calkyl etc.

p27 protein inducer

It is intended to provide a compound represented by the formula (1): [wherein Ar is an arylene group to be attached selected from the following formula (2): (wherein * represents a binding site to a nitrogen atom and ** represents a binding site to T); T represents &#x2014;(O)&#x2014;R; R represents a C-Calkyl group or the like; n represents 0 or 1; X represents O or the like; R, Rand Rare independently selected from a hydrogen atom or C-Calkyl; or Rand Rmay join together with an urea structure containing the nitrogen atoms to which they bind to form a 5- or 6-membered heterocycle; Y represents CH or N], or a pharmaceutically acceptable salt thereof or a prodrug thereof and a pharmaceutical composition containing the same.

Pyrazolopyridine and pyrrolopyridine multikinase inhibitors

The present invention provides a compound represented by general formula (1) below or a pharmaceutically acceptable salt thereof: wherein: X is selected from heteroaryl etc., Yand Yare selected from &#x2014;N&#x2550; etc., Yand Yare selected from &#x2014;CH&#x2550; etc., A is selected from sulfamide etc., Ris selected from hydrogen etc., and Ris selected from Calkyl etc. The compound or salt has sufficiently high antitumor activity, and is useful in the treatment of cell proliferative disorders, particularly cancers. The present invention also provides a pharmaceutical composition containing the compound or salt as an active ingredient.

Coumarin derivative having antitumor activity

The object of the present invention is to provide a compound useful for the prevention and treatment of viral infectious diseases, and particularly liver diseases caused by HCV infection due to its having a high degree of replication inhibitory activity against HCV, its production method, an intermediate compound useful for its production and a pharmaceutical composition containing these compounds, and the present invention relates to a compound represented by the formula (I): 

Compound having anti-HCV activity and process for producing the same

Dolastatin 10 derivatives

Growing community of inventors

Kamakura, Japan

Fumio Watanabe